Introduction
Kidney transplantation is the preferred treatment for patients with ESRD. Transplantation avoids the various complications associated with dialysis and is associated with a lower mortality and morbidity than is hemodialysis. The pathological link among infection, immune dysregulation, and cardiovascular disease, and the inflammatory response is being increasingly recognized in transplant recipients. Patients with CKD are known to be both 25hydroxyvitamin D (25OHD3) and 1,25-dihydroxyvitamin D (1, 25 [OH]2D3) deficient. Several observational studies have shown that treatment of ESRD patients with vitamin D analogs is associated with improved survival. 1,25(OH)2-D3 has long been recognized to have an immune regulatory function besides its role in calcium homeostasis. There is evidence in literature that indicates that 1,25(OH)2-D3 could have an important role in the regulation of immune function. This could have important clinical implications. Transplant physicians and surgeons should understand that vitamin D has a variety of immunological actions which can have important effect on patient and graft survival after transplantation. 1 
Vitamin D physiology
Vitamin D2 (ergocalciferol) is obtained from various food and vitamin sources, whereas vitamin D3 (cholecalciferol) is generated for the most part after skin exposure to ultraviolet B radiation. The first step in the metabolic activation of vitamin D is hydroxylation of ergocalciferol and cholecalciferol in the liver, to form 25OHD3. Almost all 25OHD3 is bound to circulating vitamin D-binding protein, which is filtered by the kidney and reabsorbed by the proximal convoluted tubules via the endocytic receptor megalin. The 25OHD3-vitamin D-binding protein complex is degraded by lysosomes in the proximal tubule, releasing 25OHD3, which translocates to the mitochondria where 25OHD3 is converted to the active vitamin D metabolite 1,25(OH)2D3 by 25-hydroxyvitamin D-1a-hydroxylase (CYP27B1). Fibroblast growth factor 23 (FGF23) attenuates renal production of 1,25(OH)2D3 by inhibiting mRNA expression of CYP27B1 in the renal proximal tubule and by simultaneously increasing expression of 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1), which results in the production of the inactive metabolite 24,25-dihydroxyvitamin D. In turn, In CKD patients various disturbances in vitamin D metabolism in addition to their classical effects on mineral bone disorder (MBD), also can have important effects on innate or adaptive immunity through various signaling pathways. Vitamin D deficiency could be a factor for triggering rejection, chronic allograft nephropathy and infections in post-transplant period. Patients with CKD are known to be both 25-hydroxyvitamin D (25OHD3) and 1,25-dihydroxyvitamin D (1, 25 [OH]2D3) deficient. Several observational studies have shown that treatment of ESRD patients with vitamin D analogues is associated with improved survival. 1,25(OH)2-D3 has long been recognized to have an immune regulatory function besides its role in calcium homeostasis. There is evidence in literature that indicates 1,25(OH)2D3 increases the activity of FGF23, which completes the feedback loop. By contrast, parathyroid hormone (PTH) increases the activity of CYP27B1, resulting in increased production of 1,25(OH)2D3. PTH secretion is inhibited by 1,25(OH)2D3. Synthesis of 1,25(OH)2D3 in various extra-renal sites occurs in both an autocrine manner and paracrine manner. 1 The majority of circulating 1,25(OH)2D3 is synthesized by proximal tubular cells in the kidney, but synthesis also occurs in extra-renal sites where cells also express mitochondrial CYP27B1. Extra-renal production of 1,25(OH)2D3 takes place in bone and in epithelial cells of the skin, lungs and colon. Extra-renal production also occurs in the para-thyroid glands and in immune cells, like activated macrophages. In severe inflammatory diseases such as sarcoidosis, 1, 25(OH)2D3 is produced in great amount in the systemic circulation to result in twice the normal level. Activation of macrophages with Toll-like receptor (TLR) ligands or IFN-g leads to induction of CYP27B1 and rapid production of 1,25(OH)2D3. However, availability of 25OHD3 within the cells is required for macrophage production of 1,25(OH)2D3, and regulatory feedback of CYP27B1 production of 1,25(OH)2D3 is not dependent on PTH. 2 
Vitamin D deficiency
In chronic kidney disease (CKD), vitamin D deficiency is increasingly recognized as a health problem as in the general population. It has been estimated that 1 billion individuals worldwide are vitamin D deficient or insufficient. Although no consensus exists on the optimal levels of 25OHD3 measured in the serum, the US Institute of Medicine has recommended after extensive investigations that mean 25OHD3 levels should be >50 nmol/l in the general population. It might be reasonable to suggest slightly higher levels (up to 75 nmol/l) in patients with CKD for effective extra-renal production of 1,25(OH)2D3 and also regulation of PTH secretion. 3 
Immune function in CKD
Vitamin D affects innate immune responses by enhancing the development of monocytes into macrophages. Vitamin D also influences chemotaxis and cytokine expression. It suppresses immunoglobulin production and B-cell proliferation and differentiation. Vitamin D has been reported to directly affect T-cell responses by inhibiting the release of Th1 and Th17 cytokines. It also induces Th2 cytokine production. Epidemiological and clinical evidence suggests significant association between vitamin D deficiency and increased incidence of autoimmune diseases. Both the innate and adaptive immune systems are affected in patients with advanced CKD and end stage renal disease (ESRD). The innate immune system recognizes pathogenic organisms and triggers a sequence of events that results in the production and secretion of cytokines and the activation of macrophages and monocytes. The adaptive immune system involves the activation of B cells and T cells, which leads to the production of antibodies and the subsequent development of immunological memory. Activation of antigen presenting cells (APCs) ultimately results in the initiation of adaptive immunity. Peripheral blood monocytes collected immediately before dialysis session have shown that renal failure milieu damages the capacity of APCs to activate adaptive immunity. Most B-cell and T-cell functions seem to be normal in CKD in the presence of healthy APCs. TLRs have a primary role in innate immunity, where they distinguish between different molecular patterns of pathogens. TLRs are widely expressed in a number of organs, including the kidney, heart, blood vessels and adipose tissue. Evidence from patients on hemodialysis shows that renal failure can also damage the function of TLRs. Degree of renal failure in patients on dialysis decreases the expression of TLRs, resulting in a decrease in the ability to produce cytokines in response to a bacterial infection. Chronic kidney disease is a state of micro-inflammation, which promotes increased production of pro inflammatory cytokines. There is also decreased clearance of these pro-inflammatory biomolecules. Circulating monocyte subpopulations with pro inflammatory characteristics are also seen in patients with CKD. Uremic toxins have been reported to cause both granulocytic dysfunction and monocytic dysfunction. Uremia is unlikely to be the only cause of neutrophil dysfunction in patients with advanced CKD. Other factors such as iron overload, oxidative stress, anemia, zinc deficiency and increased intracellular calcium are also known to influence neutrophil function. Uremia has a major role in neutrophil dysfunction in CKD, as it decreases the function of both dendritic cells and macrophages resulting in modified co-stimulatory molecules such as CD40, CD80, and CD86. Uremia is a state of immune dysregulation which results in impaired immune response to infection with misdirected inflammatory response, leading to continued inflammation. In CKD patients, vitamin D deficiency is a major problem. It can result in dysfunction of both innate and adaptive immune systems. Deficiency of vitamin D is also associated with increased micro inflammation. 4, 5 Levels of both the inactive 25-hydroxyvitamin D as well as active form 1,25-dihydroxy-vitamin D are decreased in patients with chronic kidney disease which persists even post renal transplantation. 1,25(OH)2D3 has been considered to have an immune regulatory function and also role in calcium homeostasis. Biological actions of 1,25(OH)2D3 are mediated through the vitamin D receptor (VDR). The VDR is present in most cells of the immune system, including T lymphocytes, neutrophils, and APCs. 1,25(OH)2D3 regulates both types of immunity by suppressing adaptive immunity thereby induces immune tolerance to transplanted organ and by potentiating the innate immune response decreases risk of infection. Both these actions of Vitamin D could have positive effect on patient survival and graft outcome in a post transplant patient. 6 
Vitamin D deficiency and immune dysfunction
A high prevalence of vitamin D deficiency has been found in pre-dialysis patients with moderate and severe chronic kidney disease as well as in patients undergoing hemodialysis Analyses of pre-transplant 25-hydroxyvitamin D3 levels showed that only about 15% of kidney transplant recipients have adequate vitamin D levels at the time of transplantation. 3 After kidney transplantation vitamin D deficiency remains a common problem. In a study of 31 kidney transplant recipients serum 25-hydroxyvitamin D3 levels were significantly lower in kidney transplant recipients compared with controls, with 10 out of 31 having undetectable serum 25-hydroxyvitamin D3 levels. 7 In long-term kidney transplant recipients reported vitamin D insufficiency (40-75 nmol per liter) to be present in 43%, deficiency (12-39 nmol per liter) in 46% and severe deficiency (<12 nmol per liter) in 5%. 8 Besides its classical actions in calcium homeostasis and bone metabolism, vitamin D plays an important role in the immune system. 4 Considering its potential to modulate the immune response, vitamin D is thought to have beneficial effects within the transplant setting. 1,25-Dihydroxyvitamin D3 inhibits the proliferation and differentiation of CD4 cells into TH1 and TH17 cells and promotes the production of TH2 and TREG cells which are considered to be protective in transplantation. 5 It also induces dendritic cells with tolerogenic properties resulting in Tcell hypo-responsiveness. This means that dendritic cells modulated by 1,25-dihydroxyvitamin D3 are able to inhibit T-cell proliferation and their cytokine production (e.g. interferon-g), thus, inducing regulatory T-cells with suppressive activity rather than effector T-cells. Given that 1,25(OH)2-D3 has a much higher affinity for the VDR than does 25(OH)D3, the assumption exists that most of the effects of vitamin D are mediated by 1,25(OH)2D3. However, circulating levels of 25(OH)D3 are 1000-fold higher than 1,25(OH)2D3 levels, and that this precursor, like 1a-OHD3, has direct effects on the VDR independent of those produced by 1,25(OH)2D3. 9, 10 In vitro studies have demonstrated that 1,25dihydroxyvitamin D3 has significant additive immunosuppressive effects with corticosteroids, cyclosporine and mycophenolate mofetil in various experimental models. 6 These effects are not limited to in vitro experiments, but could also be demonstrated in rat models of allograft rejection. 11, 12 In small retrospective studies, a beneficial impact of calcitriol on graft function administration has been reported in kidney transplant recipients. Graft survival improved with reduced incidence of acute rejection episodes but the study was not adequately powered. 13, 14 In several studies beneficial effects of active vitamin D on progression of chronic kidney disease were documented, either by interfering with the transforming growth factor beta-1 (TGF-b1) signaling pathways or as a negative regulator of renin angiotensinaldosterone system, yet both are considered to be important modulators of the progression of renal insufficiency and development of chronic allograft nephropathy. 1,25-Dihydroxyvitamin D3 has been reported not only to prolong graft survival but also to prevent histological changes typically found in chronic allograft nephropathy by altering TGF-b1 and matrix regulating molecules in a rat model of chronic allograft nephropathy. 17 There is some evidence that low 25-hydroxyvitamin D3 levels are associated with an increased risk of infections and malignancy. 4 Evolution of graft GFR after transplant appears to be imprinted at an early stage by early graft function. The estimated GFR (eGFR) reached at 1 year after transplantation is critically associated with allograft outcome. Vitamin D is a critical hormone controlling mineral homeostasis. It promotes phosphate and calcium absorption by the gut and increases calcium reabsorption by the renal distal tubule, thereby providing the positive calcium and phosphorus flux required for bone mineralization. Parathyroid hormone (PTH) and hypophosphatemia increase CYP27B1 expression in the proximal tubular cells, whereas the phosphatonin secretion induced by fibroblast growth factor-23 (FGF-23) decreases it. Recent research has expanded the spectrum of vitamin D actions beyond mineral metabolism. Concordant evidence sustains a wide range of unconventional vitamin D action on the immune, cardiovascular, and renal systems. Vitamin D signaling protects against CKD progression in various models of CKD. Calcitriol and paricalcitol, two agonists of VDR signaling, have been shown to lessen albuminuria in patients with IgA nephropathy and diabetic nephropathy, respectively. Two communitybased studies and a small observational study in CKD found an association between low 25(OH)D levels and the risk of ESRD or eGFR decline. Transplant recipients frequently have low 25(OH)D and 1,25(OH)D levels, especially early after transplantation. Whether these modifiable variables influence kidneys function or transplant outcome is not known. Association of 3-month vitamin D status with early mortality and allograft loss, link between vitamin D status at 3 months and measured GFR (mGFR) reached at 12 months after transplantation and association between vitamin D status at 3 months after transplantation and graft interstitial fibrosis and tubular atrophy progression between 3 and 12 months have been reported in some recent studies. 15 By binding its nuclear receptor (VDR), the steroid hormone 1,25-dihydroxyvitamin D [1,25(OH)2D3], the active form of vitamin D, regulates the expression of target genes that encode proteins involved in calcium homoeostasis and bone metabolism. Besides this classical role, it has been demonstrated that vitamin D is able to maintain tolerance and promote protective immunity. Almost all immune cells, both those of the innate response and those of the adaptive response, express receptors for active vitamin D (VDR) and are also capable of synthesizing the active vitamin D metabolite. Vitamin D affects innate immune responses by enhancing the development of monocytes into macrophages and by influencing their chemotaxis and cytokine expression; at the same time, vitamin D suppresses immunoglobulin production and B-cell proliferation and differentiation and directly affects T-cell response by inhibiting the release of Th1 and Th17 cytokines and by inducing Th2 cytokine production. Additionally, epidemiological and clinical evidence suggested a significant association between vitamin D deficiency and an increased incidence of autoimmune diseases. 16 
Conclusions
We have also reported high prevalence of vitamin D deficiency in renal transplant recipients and its impact on post transplant graft outcome and function. There was high incidence of vitamin D deficiency and insufficiency in ESRD patients (69.2%) which increased further to 80.6% at 3 months after kidney transplant. 1,25(OH)2 D3 levels also decreased after transplant with concomitant increase in VDR activity but it was still less than normal controls. FGF-23 levels quickly came down to normal levels by 3 months post transplant. At 6 months post transplant both VDR and 1,25(OH)2D3 improved but were still less than controls. There was normalization of serum PO4 levels by 3 months post transplant. Vitamin D deficiency at time of transplant correlated with lower eGFR at 3 months and one-year transplantation. Higher (>20 ng/ml) pretransplant Vitamin D levels also predicted better estimated eGFR at 3 months and one-year post transplant. At three-month post transplant, despite normalization of graft function and similar FGF-23 and 25(OH) vitamin D, Ca, PO 4 levels as in normal controls, transplant patients had significantly lower active 1,25(OH)2 vitamin D levels as compared to control and pretransplant levels. The post-transplant VDR activity improved but was still less than normal controls. Thus the dysregulated mineral metabolism continued after kidney transplant despite improvement in renal function and normalization of FGF-23. 17 In summary, in CKD patients various disturbances in vitamin D metabolism, in addition to their classical effects on mineral bone disorder (MBD), also can have important effects on innate-adaptive immunity through various important signaling pathways. Vitamin D deficiency could be a factor for triggering rejection, chronic allograft nephropathy and infections in post-transplant period.
